Form 4: Nektar Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 186 shares of common stock on August 18, 2026 for $71.98 per share.
Summary
- Open-market sale: disposed of 186 Common Stock at $71.98 ($13,388) on August 18, 2026; holds 9,570 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $13,388 of stock on the open market.
Insider Transactions
Jonathan Zalevsky — Officer (Chief R&D Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-18 | Open-market sale | Common Stock | 186 | $72 | $13.4K | 9,570 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-18 | Open-market sale (186 shares) |
Keywords
insider transaction, Form 4, NKTR, NEKTAR THERAPEUTICS, bearish, Jonathan Zalevsky
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.